Namita Diagnostic Research Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 18 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 6.86%
(FY 2023)
- Ebitda 6.86%
(FY 2023)
- Net Worth -34.19%
(FY 2023)
- Total Assets 0.30%
(FY 2023)
About Namita Diagnostic Research
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aditya Sarabhai and Namita Shah serve as directors at the Company.
- CIN/LLPIN
U45202GJ2006PTC049387
- Company No.
049387
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Namita Diagnostic Research?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Sarabhai  | Director | 01-Oct-2008 | Current |
| Namita Shah | Director | 16-Nov-2006 | Current |
Financial Performance and Corporate Structure Insights of Namita Diagnostic Research.
Namita Diagnostic Research Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 6.86% increase in profit. The company's net worth observed a substantial decline by a decrease of 34.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Namita Diagnostic Research?
In 2023, Namita Diagnostic Research had a promoter holding of 99.90% and a public holding of 0.10%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Motherson Buildwell Private LimitedActive 20 years 7 months
Aditya Sarabhai and Namita Shah are mutual person
- Scientific Pathology Laboratories Private LimitedActive 41 years 11 months
Aditya Sarabhai and Namita Shah are mutual person
- Virendra Diagnostic Research Private LimitedActive 18 years 30 days
Aditya Sarabhai and Namita Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Namita Diagnostic Research?
Unlock and access historical data on people associated with Namita Diagnostic Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Namita Diagnostic Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Namita Diagnostic Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
